Redefining hope
for patients with glioblastoma
mission
Glioblastoma (GBM) remains one of the most aggressive and lethal cancers, with a median survival of only 15 months and no therapeutic progress in over two decades.
The challenge lies in its immunosuppressive tumor microenvironment, dominated by myeloid cells that exhaust T-cell function and promote tumor growth.
Technology
GlioCART addresses the key barriers in glioblastoma – immunosuppression and antigen escape – through its dual-action CAR-T therapy, targeting not only tumor cells but also reprogramming tumor-supporting myeloid cells into active immune effectors.
Our vision is to extend the reach of CAR-T therapy beyond hematologic malignancies, unlocking durable efficacy in solid tumors, starting with glioblastoma and expanding into other myeloid-driven cancers.
